185 related articles for article (PubMed ID: 29857083)
1. Modelling heterogeneity in viral-tumour dynamics: The effects of gene-attenuation on viral characteristics.
Jenner A; Yun CO; Yoon A; Kim PS; Coster ACF
J Theor Biol; 2018 Oct; 454():41-52. PubMed ID: 29857083
[TBL] [Abstract][Full Text] [Related]
2. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
[TBL] [Abstract][Full Text] [Related]
3. The role of JNK phosphorylation as a molecular target to enhance adenovirus replication, oncolysis and cancer therapeutic efficacy.
Wechman SL; Rao XM; Gomez-Gutierrez JG; Zhou HS; McMasters KM
Cancer Biol Ther; 2018; 19(12):1174-1184. PubMed ID: 30067431
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic Replication of E1b-Deleted Adenoviruses.
Cheng PH; Wechman SL; McMasters KM; Zhou HS
Viruses; 2015 Nov; 7(11):5767-79. PubMed ID: 26561828
[TBL] [Abstract][Full Text] [Related]
5. pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis.
Choi JW; Jung SJ; Kasala D; Hwang JK; Hu J; Bae YH; Yun CO
J Control Release; 2015 May; 205():134-43. PubMed ID: 25575865
[TBL] [Abstract][Full Text] [Related]
6. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
[TBL] [Abstract][Full Text] [Related]
7. Ixovex-1, a novel oncolytic E1B-mutated adenovirus.
Anwar M; Arendt ML; Ramachandran M; Carlsson A; Essand M; Akusjärvi G; Alusi G; Öberg D
Cancer Gene Ther; 2022 Nov; 29(11):1628-1635. PubMed ID: 35596069
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic adenoviruses: design, generation, and experimental procedures.
Davydova J; Yamamoto M
Curr Protoc Hum Genet; 2013 Jul; Chapter 12():Unit 12.14. PubMed ID: 23853080
[TBL] [Abstract][Full Text] [Related]
9. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
10. Concepts in Oncolytic Adenovirus Therapy.
Mantwill K; Klein FG; Wang D; Hindupur SV; Ehrenfeld M; Holm PS; Nawroth R
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638863
[TBL] [Abstract][Full Text] [Related]
11. 2-aminopurine enhances the oncolytic activity of an E1b-deleted adenovirus in hepatocellular carcinoma cells.
Sharon D; Schümann M; MacLeod S; McPherson R; Chaurasiya S; Shaw A; Hitt MM
PLoS One; 2013; 8(6):e65222. PubMed ID: 23750246
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy.
Kim J; Cho JY; Kim JH; Jung KC; Yun CO
Cancer Gene Ther; 2002 Sep; 9(9):725-36. PubMed ID: 12189522
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA.
Gao Y; Zhu Y; Huang X; Ai K; Zheng Q; Yuan Z
Int J Oncol; 2015 Aug; 47(2):668-78. PubMed ID: 26081241
[TBL] [Abstract][Full Text] [Related]
14. A mathematical model of oncolytic virotherapy with time delay.
Wang ZZ; Guo ZM; Smith H
Math Biosci Eng; 2019 Mar; 16(4):1836-1860. PubMed ID: 31137188
[TBL] [Abstract][Full Text] [Related]
15. Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin.
Yoon AR; Kim JH; Lee YS; Kim H; Yoo JY; Sohn JH; Park BW; Yun CO
Hum Gene Ther; 2006 Apr; 17(4):379-90. PubMed ID: 16610926
[TBL] [Abstract][Full Text] [Related]
16. Cancer gene therapy with oncolytic adenoviruses.
Guse K; Hemminki A
J BUON; 2009 Sep; 14 Suppl 1():S7-15. PubMed ID: 19785073
[TBL] [Abstract][Full Text] [Related]
17. Advance in herpes simplex viruses for cancer therapy.
Liu S; Dai M; You L; Zhao Y
Sci China Life Sci; 2013 Apr; 56(4):298-305. PubMed ID: 23564184
[TBL] [Abstract][Full Text] [Related]
18. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
[TBL] [Abstract][Full Text] [Related]
19. E4orf1 limits the oncolytic potential of the E1B-55K deletion mutant adenovirus.
Thomas MA; Broughton RS; Goodrum FD; Ornelles DA
J Virol; 2009 Mar; 83(6):2406-16. PubMed ID: 19129452
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the E3 and L3 regions for arming oncolytic adenoviruses to achieve a high level of tumor-specific transgene expression.
Robinson M; Ge Y; Ko D; Yendluri S; Laflamme G; Hawkins L; Jooss K
Cancer Gene Ther; 2008 Jan; 15(1):9-17. PubMed ID: 17853920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
